3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Pituitary Neoplasms
4
Thyroid Cancer, Papillary
2
Neuroendocrine Tumors
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Pituitary Diseases
1
Pheochromocytoma
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Lymphatic Metastasis
1
Insulinoma
1
Infertility
1
Extranodal Extension
1
Esthesioneuroblastoma, Olfactory
1
Adrenal Gland Neoplasms
1
Adenocarcinoma, Follicular
1
Acromegaly
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Surgical Procedures, Operative
×
Endocrine
×
Clear all
NCT03012789
2024-04-30
NETest_Sx
Wren Laboratories LLC
Phase NA
Active not recruiting
40 enrolled
NCT04066322
2019-09-24
RMPanNET
Fudan University
Unknown
180 enrolled